Sagimet Biosciences Inc
For the period ended Dec 31, 2023. Filed Mar 25, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 25, 2024
SGMT$10.83+9.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
(in thousands, except for share and per share amounts)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · December 31, | ||||||
| | 2023 | 2022 | ||||
| Assets | | | | | | |
| Current assets: · · | ||||||
| Cash and cash equivalents | | $75,139 | | $158 | ||
| Marketable securities | | 19,758 | | 32,187 | ||
| Prepaid expenses and other current assets | | | 1,749 | | | 447 |
| Total current assets | | | 96,646 | | | 32,792 |
| Operating lease right-of-use assets | | | 73 | | | 212 |
| Deposits | | — | | 27 | ||
| Total assets | | $96,719 | | $33,031 | ||
| Liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) | | | ||||
| Current liabilities: | | | ||||
| Accounts payable | | $186 | | $1,125 | ||
| Accrued expenses and other current liabilities (includes $31 and $0 payable to related parties as of December 31, 2023 and 2022, respectively) | | 5,403 | | 4,021 | ||
| Operating lease liabilities | | 65 | | 133 | ||
| Total current liabilities | | 5,654 | | 5,279 | ||
| Long-term liabilities: | | | ||||
| Operating lease liabilities, less current portion | | — | | 78 | ||
| Warrant liability | | — | | 4 | ||
| Total liabilities | | | 5,654 | | 5,361 | |
| Commitments and contingencies (Note 8) | | | ||||
| Redeemable convertible preferred stock: $0.0001 par value; no shares authorized, issued, or outstanding at December 31, 2023; 1,373,810,170 shares authorized and 1,373,730,625 shares issued and outstanding at December 31, 2022; liquidation value of $232,963 at December 31, 2022 | | | — | | 214,620 | |
| Stockholders’ equity (deficit): | | | ||||
| Undesignated preferred stock: $0.0001 par value; 10,000,000 and no shares authorized at December 31, 2023 and 2022, respectively. No shares issued and outstanding at December 31, 2023 and 2022, respectively | | | — | | | — |
| Common stock, $0.0001 par value: no shares authorized, issued, or outstanding at December 31, 2023; 1,608,370,000 shares authorized and 185,084 shares issued and outstanding at December 31, 2022 | | — | | 1 | ||
| Series A common stock, $0.0001 par value: 500,000,000 shares authorized and 21,375,402 shares issued and outstanding at December 31, 2023; no shares authorized, issued and outstanding at December 31, 2022 | | | 2 | | | — |
| Series B common stock, $0.0001 par value: 15,000,000 shares authorized and 1,520,490 shares issued and outstanding at December 31, 2023; no shares authorized, issued and outstanding at December 31, 2022 | | | — | | | — |
| Additional paid-in capital | | 340,777 | | 35,001 | ||
| Accumulated other comprehensive income (loss) | | 30 | | (84) | ||
| Accumulated deficit | | (249,744) | | (221,868) | ||
| Total stockholders’ equity (deficit) | | | 91,065 | | (186,950) | |
| Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) | | $96,719 | | $33,031 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.